Howard Hughes Medical Institute maintained its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 125,000 shares of the company’s stock at the end of the 2nd quarter. Howard Hughes Medical Institute’s holdings in Teva Pharmaceutical Industries Limited were worth $4,153,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. increased its position in Teva Pharmaceutical Industries Limited by 2.7% in the first quarter. Advisors Asset Management Inc. now owns 24,294 shares of the company’s stock worth $780,000 after purchasing an additional 643 shares during the last quarter. Comerica Bank increased its position in Teva Pharmaceutical Industries Limited by 21.3% in the first quarter. Comerica Bank now owns 102,913 shares of the company’s stock worth $3,265,000 after purchasing an additional 18,092 shares during the last quarter. British Columbia Investment Management Corp increased its position in Teva Pharmaceutical Industries Limited by 8.1% in the first quarter. British Columbia Investment Management Corp now owns 111,905 shares of the company’s stock worth $3,591,000 after purchasing an additional 8,400 shares during the last quarter. Karp Capital Management Corp bought a new stake in Teva Pharmaceutical Industries Limited in the first quarter worth $5,625,000. Finally, Advantage Investment Management LLC increased its position in Teva Pharmaceutical Industries Limited by 11.2% in the first quarter. Advantage Investment Management LLC now owns 22,325 shares of the company’s stock worth $716,000 after purchasing an additional 2,248 shares during the last quarter. Hedge funds and other institutional investors own 56.87% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Howard Hughes Medical Institute Continues to Hold Holdings in Teva Pharmaceutical Industries Limited (TEVA)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/16/howard-hughes-medical-institute-continues-to-hold-holdings-in-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 1.42% during mid-day trading on Friday, reaching $18.10. 20,967,151 shares of the company were exchanged. The stock’s market capitalization is $18.39 billion. The stock’s 50-day moving average price is $19.00 and its 200-day moving average price is $28.55. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $51.61.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.25 earnings per share. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were given a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 1.88%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.36%.

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald set a $31.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Vetr cut shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price target on the stock. in a research report on Thursday, June 22nd. BidaskClub cut shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Citigroup Inc. cut shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $32.00 to $19.00 in a research report on Wednesday, August 16th. Finally, Maxim Group restated a “hold” rating and issued a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Five research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and a consensus price target of $31.42.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.